MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab versus Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).
      Google Scholar   
Citation:
J Clin Oncol vol 42 (4_Suppl) TPS714
Meeting Instance:
ASCO GU 2024
Year:
2024
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24 CA196171, U10CA180863 (CCTG)  
Corr. Author:
 
Authors:
                             
Networks:
 
Study
Alliance-A032001
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: